

Probiodrug

Early PQ912 data for Huntington's; AD data soon

FY16 company results

Pharma & biotech

Probiodrug's new preclinical data showed that PQ912 demonstrated efficacy in Huntington's disease (HD) in an animal model. Subject to further preclinical work, PQ912 could be fast-tracked to the clinic, which would diversify Probiodrug's R&D pipeline with a new indication. Much will depend on the outcome of the company's milestone clinical Phase IIa SAPHIR trial with PQ912 for Alzheimer's disease (AD) with the data readout shortly. PQ912 is a first-in-class small molecule glutamyl cyclase (QC) inhibitor and represents a differentiated approach in the AD field. We value Probiodrug at €345m or €42.1/share.

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/15	0.0	(13.5)	(1.96)	0.0	N/A	N/A
12/16	0.0	(13.8)	(1.81)	0.0	N/A	N/A
12/17e	0.0	(10.5)	(1.28)	0.0	N/A	N/A
12/18e	0.0	(8.7)	(1.06)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

FY16 results in line with expectations

Probiodrug reported 2016 results in line with our estimates. R&D spend in FY16 was €11.0m, vs our expectation of €11.1m, while G&A expenditure of €2.9m was lower than our €3.3m estimate indicating good cost management. Probiodrug reported cash of €21.9m at end FY16, which included a capital raise of €14.9m in October 2016. The company guided that the net loss in 2017 could be lower than in 2016 (€13.9m) since R&D costs will decrease with the SAPHIR trial winding down.

All eyes on SAPHIR data readout

Probiodrug's Phase IIa SAPHIR is due to report results before mid-2017. The trial is investigating the effects of PQ912 in AD with safety and tolerability being the primary endpoints; however, secondary endpoints will provide insights into the effect on the pathology of the disease. Since the treatment duration in Phase IIa is a relatively short three months, the R&D strategy after the SAPHIR trial will depend on results. Presuming the safety profile is confirmed, the next goal would be to trial PQ912 for a longer treatment period in the form of a Phase IIb or Phase III study. Obtaining cognition improvement over a three-month period of treatment would be a best-case scenario, but we do not believe this is a prerequisite to establishing an attractive partnership deal before moving into late-stage development.

Valuation: Slightly upped to €345m

Our valuation of Probiodrug is slightly increased, from €337m or €41.2/share, to €345m or €42.1/share due to rolling our model forward, which offsets the lower cash position of €21.9m. Our model suggests cash should be sufficient to fund operations throughout 2018, which gives enough time, post-data readout, to share future development strategy and progress with potential partners depending on the results. The outcome of the Phase IIa trial is the main catalyst in the near term.

12 April 2017

Price €17.99

Market cap €147m

Net cash (€m) at end Q416 21.9

Shares in issue 8.2m


Free float 50%

Code PBD

Primary exchange Euronext Amsterdam

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs 14.3 (2.0) (20.0)

Rel (local) 12.7 (8.0) (32.7)

52-week high/low €23.8 €15.1

Business description

Probiodrug is a German biopharmaceutical company developing its clinical pipeline for the treatment of Alzheimer's disease. Lead product candidate PQ912 is in Phase IIa. PQ912 is a small molecule inhibitor of glutamyl cyclase (QC), which is essential for the formation of pGlu-Aβeta. Two further products are in preclinical stages.

Next events

PQ912 Phase IIa data Q217

Q117 results 12 May 2017

Q217 results 31 August 2017

Analysts

Jonas Peciulis +44 (0)20 3077 5728

healthcare@edisongroup.com

[Edison profile page](#)

Probiodrug is a research client of Edison Investment Research Limited

Preclinical data support new PQ912 application

Probiodrug's preclinical data revealed that PQ912 demonstrated efficacy in HD in a well characterised model. BACHD mice with human gene coding mutant protein huntingtin (mHTT), a hallmark of the disease, were used in the study. Probiodrug will present the results at the 12th Annual HD Therapeutics Conference of the CHDI Foundation on 23 April in Malta; the headline findings include:

- mHTT levels in the brain were reduced by around 30% after treating the mice for 18 weeks with PQ912.
- The mHTT reduction was associated with improvement in the pathophysiology of the disease:
 - reduction of inflammation marker the GFAP-protein;
 - normalisation of abnormal body weight gain; and
 - normalisation of several mRNA markers coding heat shock proteins, which can prevent the accumulation of misfolded mHTT and thus its toxicity.

Probiodrug hypothesised that these effects may result from an inhibition of similar molecular mechanisms that were already well explored in AD. While encouraging, this is still the first preclinical data set released, so it is not clear whether this would translate to clinical efficacy. The company has not revealed further development strategy yet; in our view, much will depend on the outcome of the SAPHIR trial due shortly. Since PQ912 has already established safety data (short term in humans and long-term toxicity data in animals), we believe that the drug candidate could be fast-tracked to studies with HD patients. This means that Probiodrug would not be a single indication company anymore, which we believe would be a welcome diversification. The company also communicated that it is exploring PQ912's potential in other conditions, such as Down's syndrome.

HD market potential

HD is an incurable, inherited disorder associated with a loss of neurons in specific locations, resulting in symptoms such as involuntary movements (chorea), dementia and behavioural changes. Estimated prevalence is 4.1-8.4 per 100,000 people, translating to a patient population in the range of 13-27k (source: [Huntington Disease](#), Medscape). HD is a progressive disease with onset in 30-40-year-olds and patients surviving 10-25 years on average. There is currently no disease modifying therapy for this condition, only various treatment options to alleviate symptoms such as chorea or improve patients' quality of life. Therefore, the progress of the disease cannot be stopped.

According to EvaluatePharma, tetrabenazine (Xenazine) is notable among the branded drugs used to alleviate chorea in HD. Xenazine is a monoamine inhibitor, which depletes neurotransmitters dopamine, noradrenaline and serotonin, altering transmission of electric signals from the brain that control movement. Marketed by Lundbeck in the US, Xenazine had \$317m in peak sales in 2015, which then fell to \$233m in 2016 after the introduction of the first generic versions. Notably, such sales were achieved with only a symptomatic drug, while a disease modifying drug would very likely achieve much higher levels, in our view.

Financials

R&D spend in FY16 was €11.0m, in line with our €11.1m. G&A expenditure of €2.9m was lower than our €3.3m estimate for FY16, indicating good cost management. We keep our FY17 R&D cost

estimate of €7.7m unchanged in line with Probiodrugs guidance that 2017 net loss may be lower than in 2016, as the SAPHIR trial is winding down. We slightly lower our FY17 G&A costs expectations to €3.1m from €3.4m and subsequently expect the 2017 EPS loss at €1.30, an improvement from our previous loss of €1.35 (Exhibit 1).

Probiodrugs reported cash of €21.9m at end FY16, which included a capital raise of €14.9m in October 2016. Our post-FY16 model suggests that this should be sufficient to fund operations into 2019. If the company is required to repay tax provisions of €2.6m (originating from 2002-2005 and with no court decision yet), then the cash reach could be to Q418.

We continue to project that if the Phase IIa trial results are positive, a licensing deal in 2017 is likely given the high profile of Probiodrugs R&D programme among the larger players in the AD field. Although our valuation includes a risk-adjusted milestone (€25m) from a partner for PQ912 that could be triggered by licensing (more details in our [initiation report](#)) our financial forecasts do not include any such income.

Exhibit 1: Summary of the main changes to our Probiodrugs financial forecasts

€m	2016			2017e			2018e
	Estimate	Actual	% change	Old	New	% change	New
Revenues	0.000	0.000	N/A	0.000	0.000	N/A	0.000
Gross profit	0.000	0.000	N/A	0.000	0.000	N/A	0.000
Research and development costs	(11.105)	(10.951)	-1%	(7.669)	(7.669)	+0%	(5.669)
Selling, general and administration costs	(3.279)	(2.909)	-11%	(3.443)	(3.054)	-11%	(3.207)
EBITDA	(14.285)	(13.680)	-4%	(11.018)	(10.508)	-5%	(8.632)
Operating profit (reported)	(14.342)	(13.777)	-4%	(11.070)	(10.640)	-4%	(8.793)
Profit before tax (rep)	(14.220)	(13.891)	-2%	(11.053)	(10.623)	-4%	(8.793)
Profit after tax (rep)	(14.220)	(13.891)	-2%	(11.053)	(10.623)	-4%	(8.793)
EPS (€, rep)	(1.82)	(1.82)	+0%	(1.35)	(1.30)	-4%	(1.07)

Source: Edison Investment Research, Probiodrugs accounts

Operational update: SAPHIR trial in focus

Probiodrugs Phase IIa [SAPHIR](#) trial is primarily a safety and tolerability study, but a set of exploratory readouts will assess PQ912's effect on the pathology of the disease. Secondary endpoints include:

- assessment of short-term memory and verbal function (neuropsychological test battery);
- functional assessments by EEG and functional MRI, which will be indicative of changes in synaptic plasticity and neuronal connectivity respectively; and
- molecular biomarkers in cerebrospinal fluid (CSF), such as pGlu-Abeta, Abeta oligomers, neurogranin and inflammatory markers.

More details about the trial design are provided in Exhibit 2.

Exhibit 2: SAPHIR clinical study design

Aim	To determine the safety, tolerability and preliminary efficacy of PQ912 in patients with early/mild AD. Exploratory readouts will be used to look for an efficacy signal to justify advancing to pivotal study.
Summary design	Multicentre (21 sites, seven EU countries), randomised, double-blind, placebo-controlled, parallel-group study.
Design details	n=110 planned, 120 enrolled. Treatment-naïve patients (no concomitant symptomatic AD medication) with mild cognitive impairment due to AD or mild dementia due to AD. MMSE score of 21-30 inclusive, CSF Aβ concentration of < 638 ng/L AND total tau > 375 ng/L OR p-tau > 52 ng/L; Tau/Aβ ratio in CSF > 0.52; positive amyloid PET if available. Half will receive PQ912, 800mg, twice a day (with an option to decrease the dose if necessary), the other half will receive placebo.
Primary endpoints	Frequency of adverse events and serious adverse events (timeframe: 12 weeks, four weeks follow-up).
Exploratory readouts	Assessments of cognitive function and change from baseline in brain functional assessments as brain functional connectivity and synaptic plasticity and molecular biomarker levels in CSF.
Start date	March 2015
Completion dates	Full results in Q217.

Source: Probiodrugs, Edison Investment Research; clinicaltrials.gov. Note: MMSE = mini mental state examination.

Probiodrug's strategy is to establish a partnership to develop PQ912 through late-stage studies. In our view, if the Phase IIa trial shows cognition improvements with a treatment time of just three months, the company would be in an excellent position to negotiate an attractive partnership deal. Nevertheless, we believe that cognition improvement is not a prerequisite for a partnership and that a partnership will depend on the data readout. As far as we are aware, Probiodrug is the only company developing a QC inhibitor, so we expect a number of players will pay close attention to the outcome of the SAPHIR trial.

Envisaging PQ912's further development, the strategy after Phase IIa will depend on the results of the trial. A base case scenario could be a Phase IIb study to evaluate the efficacy over a longer treatment period based on encouraging signals in exploratory readouts. In the case of very strong signals in several readout categories, this would allow going directly into a pivotal longer treatment study.

Valuation

We value Probiodrug at €345m or €42.1/share, up from €337m or €41.2/share previously, due to rolling our model forward, which offsets the lower cash position of €21.9m. We are interested to see progress with PQ912 for HD, which we would add to our valuation upon entering clinical development. The breakdown of our rNPV valuation, which uses a discount rate of 12.5%, is shown in Exhibit 3. Our valuation only includes PQ912, with no value assigned to the preclinical pipeline given its earlier stage of development. Full details are discussed in our last [outlook report](#).

Exhibit 3: Probiodrug rNPV valuation

Product	Indication	Launch	Peak sales (€m)	Value (€m)	Probability	rNPV (€m)	NPV/share (€/share)
PQ912	Alzheimer's disease	2022	6,200	1,240.8	25%	323.1	39.5
Net cash				21.9	100%	21.9	2.7
Valuation				1,262.7		345.0	42.1

Source: Edison Investment Research. Note: peak sales are rounded to the nearest €100m.

Exhibit 4: Financial summary

	€'000s	2012	2013	2014	2015	2016	2017e	2018e
Year end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS								
Revenue		6	0	0	0	0	0	0
Cost of Sales		0	0	0	0	0	0	0
Gross Profit		6	0	0	0	0	0	0
Research and development		(9,255)	(8,004)	(8,008)	(10,158)	(10,951)	(7,669)	(5,669)
EBITDA		(10,206)	(9,387)	(11,173)	(13,337)	(13,680)	(10,508)	(8,632)
Operating Profit (before amort. and except.)		(10,521)	(9,675)	(11,241)	(13,363)	(13,700)	(10,534)	(8,658)
Intangible Amortisation		(37)	(26)	(26)	(30)	(77)	(106)	(134)
Exceptionals		0	0	0	0	0	0	0
Other		0	0	0	0	0	0	0
Operating Profit		(10,558)	(9,701)	(11,267)	(13,393)	(13,777)	(10,640)	(8,793)
Net Interest		(314)	(106)	(170)	(112)	(114)	17	0
Profit Before Tax (norm)		(10,835)	(9,781)	(11,411)	(13,475)	(13,814)	(10,518)	(8,658)
Profit Before Tax (FRS 3)		(10,872)	(9,807)	(11,437)	(13,505)	(13,891)	(10,623)	(8,793)
Tax		(656)	0	0	0	0	0	0
Profit After Tax (norm)		(11,491)	(9,781)	(11,411)	(13,475)	(13,814)	(10,518)	(8,658)
Profit After Tax (FRS 3)		(11,528)	(9,807)	(11,437)	(13,505)	(13,891)	(10,623)	(8,793)
Average Number of Shares Outstanding (m)		4.1	4.3	4.9	6.9	7.6	8.2	8.2
EPS - normalised (€)		(2.84)	(2.30)	(2.35)	(1.96)	(1.81)	(1.28)	(1.06)
EPS - normalised and fully diluted (€)		(2.84)	(2.30)	(2.35)	(1.96)	(1.81)	(1.28)	(1.06)
EPS - (IFRS) (€)		(2.85)	(2.30)	(2.35)	(1.97)	(1.82)	(1.30)	(1.07)
Dividend per share (€)		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		100.0	n/a	n/a	n/a	n/a	n/a	n/a
EBITDA Margin (%)		n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Margin (before GW and except.) (%)		n/a	n/a	n/a	n/a	n/a	n/a	n/a
BALANCE SHEET								
Fixed Assets		996	425	186	140	167	152	109
Intangible Assets		67	101	82	56	96	107	90
Tangible Assets		926	321	101	81	68	42	16
Investments		3	3	3	3	3	3	3
Current Assets		9,009	5,856	21,294	21,726	22,199	10,963	2,284
Stocks		18	0	0	0	0	0	0
Debtors		5	0	0	0	0	0	0
Cash		7,726	4,421	20,920	21,361	21,897	10,661	1,982
Other		1,260	1,435	374	365	302	302	302
Current Liabilities		(3,570)	(9,320)	(4,580)	(4,911)	(5,140)	(4,263)	(4,083)
Creditors		(3,570)	(3,974)	(4,580)	(4,911)	(5,140)	(4,263)	(4,083)
Short term borrowings		0	(5,346)	0	0	0	0	0
Long Term Liabilities		(1,070)	(1,265)	(929)	(822)	(850)	(850)	(850)
Long term borrowings		0	0	0	0	0	0	0
Other long term liabilities		(1,070)	(1,265)	(929)	(822)	(850)	(850)	(850)
Net Assets		5,365	(4,304)	15,971	16,133	16,376	6,003	(2,540)
CASH FLOW								
Operating Cash Flow		(12,090)	(8,477)	(10,540)	(12,149)	(13,255)	(11,136)	(8,562)
Net Interest		22	9	(54)	0	0	17	0
Tax		28	9	5	2	0	0	0
Capex		(64)	(4)	(2)	(6)	(7)	0	0
Acquisitions/disposals		0	0	0	0	0	0	0
Financing		9,516	(188)	32,436	12,594	13,798	(117)	(117)
Dividends		0	0	0	0	0	0	0
Net Cash Flow		(2,588)	(8,651)	21,845	441	536	(11,236)	(8,679)
Opening net debt/(cash)		(10,314)	(7,726)	925	(20,920)	(21,361)	(21,897)	(10,661)
HP finance leases initiated		0	0	0	0	0	0	0
Other		0	0	0	(0)	0	0	0
Closing net debt/(cash)		(7,726)	925	(20,920)	(21,361)	(21,897)	(10,661)	(1,982)

Source: Probiobdrug accounts, Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Probiobrug and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE data is permitted without FTSE's express written consent.